Maria Di Ioia

Chieti, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Predictors of subsequent relapse-independent progression after high-efficacy therapy in relapsing multiple sclerosis.

Predictors of subsequent relapse-independent progression after high-efficacy therapy in relapsing multiple sclerosis.

Journal: Frontiers in immunology
Published: July 12, 2026

Contribution of Metabolomics to Multiple Sclerosis Diagnosis, Prognosis and Treatment.

Contribution of Metabolomics to Multiple Sclerosis Diagnosis, Prognosis and Treatment.

Journal: International journal of molecular sciences
Published: September 15, 2021

Data of safety in a single-center alemtuzumab treated population.

Data of safety in a single-center alemtuzumab treated population.

Journal: Data in brief
Published: November 29, 2019

Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center.

Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center.

Journal: Multiple sclerosis and related disorders
Published: April 02, 2019

Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid.

Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid.

Journal: International journal of molecular sciences
Published: January 28, 2019

Metabolomic Signature in Sera of Multiple Sclerosis Patients during Pregnancy.

Metabolomic Signature in Sera of Multiple Sclerosis Patients during Pregnancy.

Journal: International journal of molecular sciences
Published: September 25, 2018

Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.

Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: January 24, 2018

Enhanced release of acid sphingomyelinase-enriched exosomes generates a lipidomics signature in CSF of Multiple Sclerosis patients.

Enhanced release of acid sphingomyelinase-enriched exosomes generates a lipidomics signature in CSF of Multiple Sclerosis patients.

Journal: Scientific reports
Published: October 19, 2017

"Nail loss after teriflunomide treatment: A new potential adverse event".

"Nail loss after teriflunomide treatment: A new potential adverse event".

Journal: Multiple sclerosis and related disorders
Published: June 27, 2017

Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine.

Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine.

Journal: Proteomics. Clinical applications
Published: July 30, 2015

An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis.

An integrated metabolomics approach for the research of new cerebrospinal fluid biomarkers of multiple sclerosis.

Journal: Molecular bioSystems
Published: February 19, 2015

Unraveling the molecular repertoire of tears as a source of biomarkers: beyond ocular diseases.

Unraveling the molecular repertoire of tears as a source of biomarkers: beyond ocular diseases.

Journal: Proteomics. Clinical applications
Published: July 25, 2014
Showing 1-12 of 18

Last Updated: 09/26/2026